Profund Advisors LLC cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.7% in the fourth quarter, HoldingsChannel reports. The firm owned 7,724 shares of the company’s stock after selling 1,023 shares during the period. Profund Advisors LLC’s holdings in IDEXX Laboratories were worth $1,208,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Zions Bancorporation bought a new stake in IDEXX Laboratories during the 3rd quarter valued at $162,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of IDEXX Laboratories by 1,000.0% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after acquiring an additional 1,000 shares during the period. SignalPoint Asset Management LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $200,000. Ledyard National Bank increased its holdings in shares of IDEXX Laboratories by 58.9% in the 4th quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock valued at $203,000 after acquiring an additional 480 shares during the period. Finally, Unio Capital LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $203,000. 87.09% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

In related news, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total transaction of $2,972,700.00. Following the transaction, the chief executive officer now directly owns 1,077,112 shares in the company, valued at approximately $177,885,046.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jonathan W. Ayers sold 2,160 shares of the business’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $167.03, for a total value of $360,784.80. Following the transaction, the chief executive officer now owns 1,077,112 shares in the company, valued at $179,910,017.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,736 shares of company stock worth $16,193,502. 2.77% of the stock is owned by company insiders.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $204.53 on Wednesday. IDEXX Laboratories, Inc. has a one year low of $146.09 and a one year high of $206.49. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The firm has a market capitalization of $17,803.54, a price-to-earnings ratio of 64.67, a P/E/G ratio of 2.51 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The firm had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. During the same period in the previous year, the business earned $0.58 EPS. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. analysts predict that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.

IDXX has been the topic of a number of analyst reports. Aegis reiterated a “sell” rating on shares of IDEXX Laboratories in a report on Friday, December 8th. BidaskClub downgraded IDEXX Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, December 16th. Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price target on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $210.00 price target on shares of IDEXX Laboratories in a report on Monday, January 29th. Finally, Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $194.00.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/14/idexx-laboratories-inc-idxx-shares-sold-by-profund-advisors-llc.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.